Table 3.

Differences in efficacy of EGFR-TKI therapy according to smoking status by subgroup.

Subgroups		Number of trials	Pooled interaction HR	P-interaction
Overall		20	0.91 (0.76–1.09)	0.31
EGFR situation	Unknown	13	0.87 (0.69–1.10)	0.24
	Wild-type	2	1.15 (0.58–2.27)	0.68
	Mutation	5	0.95 (0.69–1.32)	0.77
Lines of therapy	>1	13	0.91 (0.71–1.17)	0.46
	1	7	0.87 (0.69–1.10)	0.25
EGFR-TKI intervention	Gefitinib	6	0.86 (0.73–1.03)	0.10
	Erlotinib	10	0.86 (0.67–1.10)	0.23
	Others	4	1.03 (0.50–2.11)	0.95
Control treatment	Placebo	8	0.88 (0.59–1.29)	0.50
	Chemotherapy	12	0.91 (0.77–1.06)	0.22